Prevention of Radial Artery Occlusion by Rivaroxaban prescription after Trans-radial access for coronary procedures: a multicentric randomized trial

hedi chaker hospital0 个研究点目标入组 512 人开始时间: 2021年10月17日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•1. Willing and able to provide written informed consent
•2.Age = 18 years and <80 years
•3.Diagnostic coronary angiography or percutaneous coronary intervention via the transradial approach

•Presence of a palpable hematoma or clinical concern of hemostasis at the transradial access site
•2.Access or attempted access at a second site - including contralateral radial artery, brachial, or femoral artery or vein
•3.Planned staged procedure, CABG or noncardiac surgery within 30 days
•4.Contraindication or high risk of bleeding with anticoagulation
•a. bleeding requiring medical attention in the previous 6 months
•b.thrombocytopenia (platelets<50 x 109/L)
•c.prior intracranial hemorrhage
•d.use of IIb/IIIa during percutaneous coronary intervention
•e.administration of thrombolytic therapy in the preceding 24 hours
•f.use of non-steroidal anti-inflammatory medications
•g.ischemic stroke or transient ischemic attack diagnosed in the last 3 months
•5.Cardiogenic shock
•6.Liver dysfunction (Child-Pugh class B or C)
•8.Unexplained anemia with a Hemoglobin below 100 g/L
•9.History of medication noncompliance or risk factor for noncompliance
•10.Active malignancy
•11.Allergy to Rivaroxaban
•12.Another indication for curative anticoagulation (atrial fibrillation thromboembolic events, intra-cardiac thrombus)
•13.CYP3A4 and P-glycoprotein inhibitor use (ex: Ticagrelor)
•14.Life expectancy <30 days
•15.Women capable of pregnancy not on birth control
•16.Chronic kidney disease with creatinine clearance of less than 30mL/min ( calculated with cockroft formula)
•17.History of anti-phosphopholipid antibody syndrome

发起方

hedi chaker hospital